代謝的に不安定なフーマレートエステルは,不可逆的な阻害剤に運動的選択性を与える
Balyn W Zaro1, Landon R Whitby1, Kenneth M Lum1
1The Skaggs Institute for Chemical Biology and Department of Chemical Physiology , 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Journal of the American Chemical Society
|December 15, 2016
まとめ
研究者らは,代謝が不安定になるようにすることで,電性薬の精度を向上させる戦略を開発しました. このアプローチは運動的選択性を高め,化学的探査と治療法を改善するために標的型タンパク質の修正を可能にします.
科学分野:
- 薬剤化学
- 化学生物学
- 薬理学について
背景:
- 電子性小分子は化学的探査機や薬として不可欠であり,しばしば不可逆的なタンパク質改変によって作用する.
- がんに対するキナーゼ阻害剤や多発性硬化症に対するディメチルフーマレートなどの共性薬は,このクラスの例です.
- 重要な課題は,選択性と有用性を低下させる可能性のある,時間依存の非ターゲットの改変です.
研究 の 目的:
- 電気愛好薬に運動的選択性を与える方法を開発する.
- 化学探知器の精度を高めるため
- 標的外反応を緩和し 標的の接触を維持する
主な方法:
- メタボリックに不安定なフーマレートエステル電粒子を組み込む改変した共性ブルトンチロシンキナーゼ (BTK) 阻害剤イブルーチニブの設計と合成.
- 改変した抑制剤の酵素代謝運動の評価
- 細胞および動物モデルにおける標的の関与と標的外反応性の評価
主要な成果:
- fumarate ester アナログは,関連する時間枠内で酵素代謝に対する脆弱性を示した.
- この代謝の不安定性は,標的タンパク質であるBTKの迅速かつ持続的な阻害を維持した.
- 細胞および動物モデルにおいて,非代謝類に比べて,標的外反応性が著しく低下した.
結論:
- 代謝的に不安定な電ophilic グループは,運動的選択性を達成するために,戦略的に共性薬に組み込まれることができます.
- このアプローチにより,特定のタンパク質と生化学的経路を正確に乱すことができます.
- この発見は,より選択的で効果的な共性療法と化学探査の開発を支援する.
関連する概念動画
Enzyme Inhibition
94.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
94.3K
Regioselective Formation of Enolates
3.6K
As depicted in the figure below, the unsymmetrical ketones can form two possible enolates: less substituted or more substituted enolates. Usually, the thermodynamic enolates are formed from the more substituted α-carbon atom, while the kinetic enolates are formed faster by deprotonation from the less substituted position. The thermodynamic enolates have lower energy, so they are more stable. But the energy required to form kinetic enolates is less.
3.6K
The Electron Transport Chain
20.8K
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
20.8K
Carboxylic Acids to Esters: Acid-Catalyzed (Fischer) Esterification Overview
21.1K
The Fischer esterification reaction was developed by the German chemist Emil Fischer in 1895. It is a condensation reaction between carboxylic acids and alcohols in an acidic medium to give esters and water.
21.1K
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
893
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
893
Drug Metabolism: Phase II Reactions
5.4K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
5.4K


